

해외 바이오의약품 임상 현황 (2020.05.11~2020.05.17)

한국바이오의약품협회, 2020.5.19.
출처: ClinicalTrials.gov

○ 미국 12건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|---|---|---|---------------------|
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IIV Fallopian Tube Cancer AJCC v8 Stage IIV Ovarian Cancer AJCC v8 Stage IIV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8 | Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs | Roswell Park Cancer Institute National Cancer Institute (NCI) | Phase 1 Phase 2 |
| NCT04362189 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | COVID-19 | Drug: HB-adMSC Drug: Placebo Drug: HC Drug: AZ | Hope Biosciences Advanced Diagnostics Healthcare Hope Biosciences Stem Cell Research Foundation | Phase 2 |
| NCT04354831 | A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection | COVID-19 | Biological: anti-SARS-CoV-2 convalescent plasma | Medical College of Wisconsin Froedtert Hospital | Phase 2 |
| NCT04343976 | Pegylated Interferon Lambda Treatment for COVID-19 | COVID-19 COVID | Drug: Pegylated interferon lambda | Raymond Chung Eiger BioPharmaceuticals Massachusetts General Hospital | Phase 2 |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage II Marginal Zone Lymphoma Ann Arbor Stage III Diffuse Large B-Cell Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage III Marginal Zone Lymphoma Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma Ann Arbor Stage IV Follicular Lymphoma Ann Arbor Stage IV Marginal Zone Lymphoma Diffuse Large B-Cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Indolent Non-Hodgkin Lymphoma | Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Drug: Parsaclisib Biological: Pegfilgrastim Drug: Prednisone Biological: Rituximab Drug: Vincristine Sulfate | Mayo Clinic National Cancer Institute (NCI) | Phase 1 |
| NCT04237623 | GM-CSF With Post-Transplant Cyclophosphamide | Transplant-Related Hematologic Malignancy | Drug: Sargramostim Other: Control Arm | Northside Hospital, Inc. | Phase 2 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Aggressive Non-Hodgkin Lymphoma ALK-Positive Large B-Cell Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Drug: Polatuzumab Vedotin Biological: Rituximab Drug: Prednisone Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Biological: Filgrastim | University of Washington National Cancer Institute (NCI) Genentech, Inc. | Phase 1 |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | Multiple Myeloma | Drug: Daratumumab | Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health | Phase 2 |
| NCT04165083 | Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYNOTE-01B) | Carcinoma, Non-Small-Cell Lung | Biological: Pembrolizumab Biological: MK-4830 | Merck Sharp & Dohme Corp. | Phase 2 |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | Locally Advanced Malignant Solid Neoplasm Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8 Unresectable Malignant Solid Neoplasm | Biological: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 Drug: VLP-encapsulated TLR9 Agonist CMP-001 | University of Southern California National Cancer Institute (NCI) | Phase 1 Phase 2 |
| NCT04152863 | Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | Advanced/Metastatic Melanoma | Biological: V937 IV Biological: V937 IT Drug: Pembrolizumab | Merck Sharp & Dohme Corp. | Phase 2 |
| NCT04285567 | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | Chronic Lymphocytic Leukemia (CLL) | Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine | Hoffmann-La Roche | Phase 3 |

○ 영국 1건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|--------------------------|------------------------------------|------------------------------------|---------|
| NCT04379076 | InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort | COVID-19 Lymphocytopenia | Drug: Interleukin-7 Drug: Placebos | Revimmune Amarex Clinical Research | Phase 2 |

해외 바이오의약품 임상 현황 (2020.05.11~2020.05.17)

한국바이오의약품협회, 2020.5.19.
출처: ClinicalTrials.gov

○ 프랑스 2건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|---|---|--|---------|
| NCT04384549 | Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers | Infection Viral, Agent as Cause of Disease Classified Elsewhere | Biological: BCG GROUP Other: PLACEBO GROUP | Assistance Publique - H c̐pitaux de Paris | Phase 3 |
| NCT04285567 | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | Chronic Lymphocytic Leukemia (CLL) | Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine | Hoffmann-La Roche | Phase 3 |

○ 독일 1건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|----------------------------|---|--|---------|
| NCT04335890 | IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma | Melanoma, Uveal Metastatic | Biological: Vaccination with IKKb matured Dendritic Cells | Hasumi International Research Foundation | Phase 1 |

○ 중국 2건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|--|--|--|--|---------|
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC | Esophageal Squamous Cell Carcinoma Stage III | Drug: Pembrolizumab Injection [Keytruda] | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| NCT04386707 | Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine | Poliomyelitis | Biological: Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age Biological: Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age Biological: Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age Biological: Three doses control wIPV at the schedule of 2,3,4 months of age | Sinovac Biotech Co., Ltd | Phase 3 |

○ 일본 1건

| NCT Number | Title | Conditions | Interventions | Sponsor/Collaborators | Phases |
|-------------|---|--|---|-----------------------|---------|
| NCT04368429 | Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age | Meningococcal Infection (Healthy Volunteers) | Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Sanofi | Phase 3 |